

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A method of inhibiting tumor growth in a cancer patient comprising administering to said patient a combination therapy comprising effective amounts of 5-Fluorouracil (5-FU) and a methylol transfer agent, said methylol transfer agent being capable of substantially enhancing antineoplastic effects of said 5-FU, substantially reducing toxic side effects of said 5-FU, or a combination thereof, wherein said methylol transfer agent has a substantial effect on activity of said 5-FU, said substantial effect being selected from the group consisting of substantially enhancing antineoplastic effects of said 5-FU, substantially reducing toxic side effects of said 5-FU, and a combination thereof, wherein said methylol transfer agent is taurolidine, taurultam or a mixture thereof.

2. (Original) The method of claim 1 wherein said tumor is a lymphoma, carcinoma or sarcoma.

3. (Original) The method of claim 1 wherein said tumor is a glioma, a neuroblastoma, an astrocytoma, carcinomatous meningitis, breast cancer, ovarian cancer, colon cancer, rectal cancer, colo-rectal cancer, prostate cancer, pancreatic cancer, CNS cancer, liver cancer, lung cancer, gastric cancer, esophageal cancer, urinary bladder cancer, leukemia, melanoma, renal cell cancer, cancer in a patient's head, or cancer in a patient's neck.

4-5. Canceled.

6. (Original) The method of claim 1 wherein said tumor is colon cancer, rectal cancer or colo-rectal cancer.

7. (Original) The method of claim 6 wherein said tumor growth is metastatic tumor growth.

8. Canceled.

9. (Original) The method of claim 7 wherein said methylol transfer agent is taurolidine, taurultam or a mixture thereof.

10. (Currently amended) A combination comprising 5-FU and a methylol transfer agent in effective amounts for simultaneous, separate or sequential use for inhibiting tumor growth in a cancer patient, said methylol transfer agent being capable of substantially enhancing antineoplastic effects of said 5-FU, substantially reducing toxic side effects of said 5-FU, or a combination thereof, wherein said methylol transfer agent has a substantial effect on activity of said 5-FU, said substantial effect being selected from the group consisting of substantially enhancing antineoplastic effects of said 5-FU, substantially reducing toxic side effects of said 5-FU, and a combination thereof, wherein said methylol transfer agent is taurolidine, taurultam, or a mixture thereof.

11. Canceled.